TY - JOUR
T1 - Status og perspektiver for behandling af de kroniske myeloproliferative neoplasier
AU - Ocias, Lukas Frans
AU - Holmström, Morten Orebo
AU - Riley, Caroline Hasselbalch
AU - Andersen, Christen Lykkegaard
AU - Rønnov-Jessen, Dorte
AU - Starklint, Jørn
AU - Frederiksen, Mikael
AU - Steffensen, Morten Saabye
AU - Bjerrum, Ole Weis
AU - Farmer, Sarah
AU - Mourits-Andersen, Torben
AU - Hasselbalch, Hans Carl
AU - Larsen, Thomas Stauffer
PY - 2015/5/4
Y1 - 2015/5/4
N2 - Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.
AB - Polycythaemia vera, essential thrombocytosis and primary myelofibrosis are closely related, clonal myeloproliferative neoplasms. Our knowledge of the underlying molecular mechanisms driving these diseases has increased dramatically during the latest ten years. Traditionally, treatment of these malignancies has focused on lowering their inherent thromboembolic risk but with the discovery of the JAK2-V617F mutation and most recently the calreticulin mutations new therapeutic options such as interferon-alpha, JAK2-inhibitors and statins are being contemplated. This article reviews these new treatment options.
M3 - Tidsskriftartikel
C2 - 25967090
VL - 177
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 19
ER -